Baclofen
How it works: Treating relapses and symptoms →
Fleqsuvy
EU: Approved nationally (not via EMA)US: FDA approved 2022
- Molecule type
- Small molecule
- Mechanism (ChEMBL)
- GABA-B receptor agonist
- Targets
- GABA-B receptor
Approvals
- USFleqsuvy · Approved2022-02-04 Source
Safety communications
None recorded.
Most-reported side effects (FDA reports)
Reports to the FDA's adverse event system (FAERS) show what people and doctors reported while taking the medicine. They do not prove the medicine caused it, and they are not rates.
93,020 reports in total, 62,170 marked serious.
- Fatigue6,501
- Pain6,415
- Drug ineffective6,054
- Fall5,803
- Nausea5,022
- Headache4,717
- Gait disturbance4,314
- Off label use4,065
- Dizziness3,808
- Muscle spasms3,788
Trials
Other trials (3)
Completed small trials, dose-finding studies and trials in other diseases.
- Baclofen, phase 3
Completed · Phase 3 · MS (type not specified) · no_result_found
- Baclofen, phase 3
Completed · Phase 3 · MS (type not specified) · no_result_found
- Baclofen, phase 3
Completed · Phase 3 · MS (type not specified) · no_result_found
For information only, not medical advice. Talk to your neurologist before changing treatment.
Hypotheses involving this medicine
Loading hypotheses…
Loading reviews and guidelines…
Lab studies
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error